Olmesartan Medoxomil Accord (Olmesartan Medoxomil)

Olmesartan Medoxil is an angiotensin II receptor blocker indicated for several cardiovascular conditions.

• Hypertension: lowers blood pressure and reduces the risk of cardiovascular events.
• Heart failure: used as part of combination therapy to improve symptoms and outcomes.
• Diabetic nephropathy: helps protect kidney function by controlling blood pressure.
• Post‑myocardial infarction: assists in long‑term blood pressure management after a heart attack.
• Stroke prevention: contributes to secondary prevention of ischemic stroke in high‑risk patients.
• Chronic kidney disease: aids in slowing disease progression when hypertension is present.

• Olmesartan medoxil is a pro‑drug that is rapidly converted to olmesartan, which selectively blocks the binding of angiotensin II to the AT‑1 receptor on vascular smooth‑muscle and adrenal cells. This inhibition prevents vasoconstriction and aldosterone release, leading to reduced peripheral resistance, lower blood pressure, and decreased sodium and water retention.

Olmesartan Medoxil Accord may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness
• Headache
• Fatigue
• Nasal congestion
• Diarrhea
• Cough

Serious or Rare Side Effects

• Angio‑edema
• Hyperkalemia
• Acute kidney injury
• Severe hypotension
• Liver enzyme elevation
• Allergic skin reactions

When prescribing Olmesartan Medoxil Accord, clinicians should consider several safety aspects.

• Renal function monitoring: assess baseline kidney function and adjust as needed.
• Electrolyte balance: watch for hyperkalemia, especially with potassium‑sparing diuretics.
• Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity.
• Hypotension risk: caution in patients with volume depletion or on other antihypertensives.
• Drug interactions: review concomitant medications for additive blood‑pressure effects.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxil Accord can interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid)

• Aliskiren (in patients with diabetes or renal impairment)
• Potassium‑supplement containing products
• Lithium (may increase serum lithium levels)

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (may reduce antihypertensive effect)
• Diuretics (enhance hypotensive response)
• ACE inhibitors or other ARBs (risk of additive renal effects)
• Cyclosporine (may increase olmesone levels)